Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men
A Proof-Of-Concept Phase 1b/2a Randomized, Vehicle, and Comparator-Controlled Study of Topical DLQ01 to Assess the Safety and Efficacy in the Treatment of Androgenetic Alopecia (AGA) in Men
In the register
The register attaches this trial to DLQ-01 (latanoprost) (DermaLiq Therapeutics), currently at “Phase 1/2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1/2
- Sponsor
- Dermaliq Therapeutics, Inc.
- Participants (registry)
- 120
- Start
- December 2022
- Primary completion
- March 2024
- Study completion
- March 2024
- Last registry update
- April 2024
- Countries
- Australia
Conditions studied: Androgenetic Alopecia
Interventions: prostaglandin F2a analogue in vehicle solution high dose, DLQ01 high dose, prostaglandin F2a analogue in vehicle solution low dose, DLQ01 low dose, active ingredient-free vehicle solution to DLQ01, DLQ01 vehicle, Minoxidil 5% Topical Solution, Regaine®
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.